Name | Number of supported studies | Average coverage | |
---|---|---|---|
astrocyte | 10 studies | 25% ± 10% | |
fibroblast | 8 studies | 20% ± 3% | |
adipocyte | 8 studies | 26% ± 4% | |
B cell | 7 studies | 23% ± 3% | |
endothelial cell | 7 studies | 27% ± 9% | |
epithelial cell | 6 studies | 30% ± 9% | |
oligodendrocyte | 6 studies | 24% ± 5% | |
oligodendrocyte precursor cell | 6 studies | 31% ± 9% | |
CD16-positive, CD56-dim natural killer cell, human | 5 studies | 22% ± 4% | |
naive B cell | 5 studies | 20% ± 3% | |
ciliated cell | 5 studies | 26% ± 9% | |
CD16-negative, CD56-bright natural killer cell, human | 4 studies | 18% ± 1% | |
glutamatergic neuron | 4 studies | 44% ± 21% | |
natural killer cell | 4 studies | 17% ± 3% | |
abnormal cell | 4 studies | 21% ± 6% | |
CD4-positive, alpha-beta T cell | 3 studies | 20% ± 3% | |
GABAergic neuron | 3 studies | 41% ± 11% | |
myofibroblast cell | 3 studies | 20% ± 2% | |
basal cell | 3 studies | 25% ± 3% | |
transit amplifying cell | 3 studies | 23% ± 6% | |
goblet cell | 3 studies | 17% ± 1% | |
neuron | 3 studies | 26% ± 7% | |
hepatocyte | 3 studies | 31% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 8730.06 | 1445 / 1445 | 100% | 21.26 | 183 / 183 |
prostate | 100% | 11286.96 | 245 / 245 | 100% | 33.19 | 502 / 502 |
skin | 100% | 8716.96 | 1809 / 1809 | 100% | 34.64 | 472 / 472 |
thymus | 100% | 20132.39 | 653 / 653 | 100% | 60.38 | 605 / 605 |
uterus | 100% | 12054.76 | 170 / 170 | 100% | 31.28 | 459 / 459 |
ovary | 100% | 13110.51 | 180 / 180 | 100% | 39.74 | 429 / 430 |
breast | 100% | 9620.37 | 459 / 459 | 100% | 32.61 | 1114 / 1118 |
kidney | 100% | 9873.64 | 89 / 89 | 99% | 24.62 | 896 / 901 |
pancreas | 100% | 5528.24 | 328 / 328 | 99% | 24.62 | 177 / 178 |
intestine | 100% | 8885.33 | 966 / 966 | 99% | 23.25 | 524 / 527 |
bladder | 100% | 9423.62 | 21 / 21 | 99% | 26.18 | 501 / 504 |
lung | 100% | 7408.47 | 577 / 578 | 99% | 26.48 | 1149 / 1155 |
stomach | 100% | 6039.02 | 359 / 359 | 99% | 23.06 | 284 / 286 |
brain | 99% | 7146.37 | 2622 / 2642 | 100% | 26.92 | 705 / 705 |
liver | 100% | 9055.96 | 226 / 226 | 99% | 21.83 | 402 / 406 |
adrenal gland | 100% | 9655.23 | 258 / 258 | 98% | 19.59 | 225 / 230 |
adipose | 100% | 9950.02 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 25.65 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 26.79 | 29 / 29 |
muscle | 100% | 12643.10 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 9386.25 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 26.82 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 16.06 | 1 / 1 |
blood vessel | 100% | 7444.54 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 6314.39 | 850 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 7028.55 | 916 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0018105 | Biological process | peptidyl-serine phosphorylation |
GO_0046326 | Biological process | positive regulation of glucose import |
GO_0072659 | Biological process | protein localization to plasma membrane |
GO_0032869 | Biological process | cellular response to insulin stimulus |
GO_0005978 | Biological process | glycogen biosynthetic process |
GO_0010748 | Biological process | negative regulation of long-chain fatty acid import across plasma membrane |
GO_0032000 | Biological process | positive regulation of fatty acid beta-oxidation |
GO_0007165 | Biological process | signal transduction |
GO_2000147 | Biological process | positive regulation of cell motility |
GO_0097473 | Biological process | retinal rod cell apoptotic process |
GO_0045725 | Biological process | positive regulation of glycogen biosynthetic process |
GO_0006417 | Biological process | regulation of translation |
GO_0071486 | Biological process | cellular response to high light intensity |
GO_0035556 | Biological process | intracellular signal transduction |
GO_0008286 | Biological process | insulin receptor signaling pathway |
GO_0032287 | Biological process | peripheral nervous system myelin maintenance |
GO_0030335 | Biological process | positive regulation of cell migration |
GO_0036211 | Biological process | protein modification process |
GO_0030334 | Biological process | regulation of cell migration |
GO_0060644 | Biological process | mammary gland epithelial cell differentiation |
GO_0090314 | Biological process | positive regulation of protein targeting to membrane |
GO_0010907 | Biological process | positive regulation of glucose metabolic process |
GO_0006006 | Biological process | glucose metabolic process |
GO_0051726 | Biological process | regulation of cell cycle |
GO_0045444 | Biological process | fat cell differentiation |
GO_0032587 | Cellular component | ruffle membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0005769 | Cellular component | early endosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005938 | Cellular component | cell cortex |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0005634 | Cellular component | nucleus |
GO_0140677 | Molecular function | molecular function activator activity |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | AKT2 |
Protein name | non-specific serine/threonine protein kinase (EC 2.7.11.1) RAC-beta serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-2) (Protein kinase B beta) (PKB beta) (RAC-PK-beta) AKT2 protein AKT serine/threonine kinase 2 |
Synonyms | |
Description | FUNCTION: AKT2 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development. Involved in the inhibition of ciliogenesis associated with RAB8-dependent cilia growth . .; FUNCTION: One of the few specific substrates of AKT2 identified recently is PITX2. Phosphorylation of PITX2 impairs its association with the CCND1 mRNA-stabilizing complex thus shortening the half-life of CCND1. AKT2 seems also to be the principal isoform responsible of the regulation of glucose uptake. Phosphorylates C2CD5 on 'Ser-197' during insulin-stimulated adipocytes. AKT2 is also specifically involved in skeletal muscle differentiation, one of its substrates in this process being ANKRD2. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase-dependent apoptosis. Phosphorylates CLK2 on 'Thr-343'. |
Accessions | A8MX96 M0R0P9 ENST00000579047.5 ENST00000578615.6 Q6P4H3 J3QL45 ENST00000584288.5 ENST00000486368.6 J3QKW1 ENST00000427375.1 J3KT31 ENST00000391844.8 P31751 ENST00000492463.6 M0R283 J3KRI8 ENST00000392038.7 [P31751-1] ENST00000497948.5 ENST00000392037.5 ENST00000596634.5 ENST00000456441.5 ENST00000601166.5 C9JIF6 A0A0A0MRF1 J3KTP4 J3KTC6 ENST00000583859.5 J3KSY8 ENST00000452077.5 ENST00000489375.5 C9JHS6 J3QLS6 ENST00000423127.5 A0A0U4CQG9 ENST00000311278.10 [P31751-2] ENST00000424901.5 [P31751-2] ENST00000578123.5 A0A5F9ZHJ8 C9JIJ1 ENST00000358335.9 M0R275 M0QZW8 C9JC83 E7EVP8 C9J258 ENST00000441941.6 ENST00000578310.1 M0QZK3 A0A1B0GXA2 ENST00000416994.6 ENST00000672890.1 ENST00000580747.5 ENST00000491778.6 ENST00000476247.6 ENST00000416362.5 |